

Zydus Cadila receives tentative approval from USFDA for Lenalidomide Capsules

Ahmedabad, India, 17 August, 2021

Zydus Cadila has received tentative approval from the USFDA to market Lenalidomide Capsules in the strengths of 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg. (USRLD: Revlimid). Lenalidomide is used to treat various types of cancers. It works by slowing or stopping the growth of cancer cells. It is also used to treat anemia in patients with certain blood/bone marrow disorders (myelodysplastic syndromes-MDS). The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad.

The group now has 320 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.

About Zydus

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs nearly 25000 people worldwide and is dedicated to creating healthier communities globally.

For further information please contact : The Corporate Communications Department Cadila Healthcare Limited Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad 382 481, India. Phone : +91-079-71800000, +91-079-48040000 www.zyduscadila.com CIN : L24230GJ1995PLC025878